Jingtian & Gongcheng Helps Biologics "Unicorn", WuXi Biologics Get Listed in Hong Kongpublish time:2017-06-19

WuXi Biologics Technology Co., Ltd. ("WuXi Biologics", stock code: 02269.HK) was listed on the Hong Kong Stock Exchange on June 13, 2017. The total funds raised by WuXi Biologics in the IPO was about HK$ 3.975 billion and the opening price was HK$ 25.00 per share, bringing the market value of the company to HK$ 32.00 billion on the first day of listing, making it the unicorn of the biomedical industry in China and a Chinese company with the highest value on Hong Kong Stock Exchange among all other Chinese companies specialized in the field of biomedicine.


WuXi Biologics has established a unique world-class and China's best integrated biopharmaceutical discovery, development and production technology and capacity platform. WuXi Biologics can provide services that cover the entire biological development process and customized solutions at any stage of the biological development process. At present, WuXi Biologics has 334 ongoing projects, of which 127 are comprehensive projects that require WuXi Biologics to provide service at all stages of biologics development. The company has propelled 15 biological agents into an experimental new drug application stage that can be used to launch global clinical trials and 32 molecules into clinical trials in China. In addition, the company has developed 191 cell lines for therapeutic protein use and 72 cell-based bioassay methods, and has produced more than 330 batches of biological agents with a success rate of 97.6%. Its clients include: AstraZeneca, Genentech, JNJ, Harbin Yu Heng, Zhejiang Pharmaceutical, Chiatai Taiqing, Hualan Gene, etc. Headquartered in Wuxi, Jiangsu Province, China, the company has set up three operating bases in Wuxi, Shanghai and Suzhou respectively, ranks first in China's biologics R&D service market and is in a market leading position on a global scale.


Jingtian & Gongcheng lawyers’ team, as the PRC legal counsel to the joint sponsor, has participated in the whole course of listing of WuXi Biologics.